http://www.mynewsdesk.com/fi/pressroom/astrazeneca/document/list MyNewsdesk-syötteet suoraan lähteestä http://www.mynewsdesk.com/fi/pressroom/astrazeneca/document/list http://www.mynewsdesk.com/images/redesign/graphics/logos/logo-small.png 128 23 sv 15 Wed, 12 Dec 2012 15:03:14 +0200 http://www.mynewsdesk.com/fi/pressroom/astrazeneca/document/view/astrazeneca-zinforo-taustamateriaalia-2012-23791?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document http://www.mynewsdesk.com/fi/pressroom/astrazeneca/document/view/astrazeneca-zinforo-taustamateriaalia-2012-23791?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document AstraZeneca AB Wed, 08 Feb 2012 08:49:08 +0200 http://www.mynewsdesk.com/fi/pressroom/astrazeneca/document/view/azn-q4_2011-press-release-17962?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document http://www.mynewsdesk.com/fi/pressroom/astrazeneca/document/view/azn-q4_2011-press-release-17962?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document AstraZeneca AB Wed, 25 Jan 2012 13:55:08 +0200 http://www.mynewsdesk.com/fi/pressroom/astrazeneca/document/view/tietoa-keuhkosyoevaestae-17716?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document http://www.mynewsdesk.com/fi/pressroom/astrazeneca/document/view/tietoa-keuhkosyoevaestae-17716?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document AstraZeneca AB Wed, 25 Jan 2012 13:54:39 +0200 http://www.mynewsdesk.com/fi/pressroom/astrazeneca/document/view/valmisteyhteenvetolyhennelmae-iressa-16923?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document http://www.mynewsdesk.com/fi/pressroom/astrazeneca/document/view/valmisteyhteenvetolyhennelmae-iressa-16923?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document AstraZeneca AB Wed, 25 Jan 2012 13:53:59 +0200 http://www.mynewsdesk.com/fi/pressroom/astrazeneca/document/view/gefitinibi-taustatiedote-17715?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document http://www.mynewsdesk.com/fi/pressroom/astrazeneca/document/view/gefitinibi-taustatiedote-17715?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document AstraZeneca AB Tue, 01 Nov 2011 13:06:28 +0200 http://www.mynewsdesk.com/fi/pressroom/astrazeneca/document/view/briliquen-valmisteyhteenvetolyhennelmae-16396?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document http://www.mynewsdesk.com/fi/pressroom/astrazeneca/document/view/briliquen-valmisteyhteenvetolyhennelmae-16396?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document AstraZeneca AB Mon, 31 Oct 2011 12:32:19 +0200 AstraZeneca Financial Summary QIII 2011 http://www.mynewsdesk.com/fi/pressroom/astrazeneca/document/view/financial-summary-qiii-2011-16368?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document http://www.mynewsdesk.com/fi/pressroom/astrazeneca/document/view/financial-summary-qiii-2011-16368?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document AstraZeneca AB Thu, 27 Oct 2011 10:25:03 +0300 http://www.mynewsdesk.com/fi/pressroom/astrazeneca/document/view/zomig-nasal-5-mg-valmisteyhteenveto-16317?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document http://www.mynewsdesk.com/fi/pressroom/astrazeneca/document/view/zomig-nasal-5-mg-valmisteyhteenveto-16317?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document AstraZeneca AB Fri, 21 Oct 2011 16:06:00 +0300 Tiedosto sisältää Vimovo kipulääkkeen valmisteyhteenvedon, jolle Lääkkeiden hintalautakunta on myöntänyt peruskorvattavuuden (42%) 1.7.2011 alkaen ohessa kuvatun käyttöaiheen mukaisesti. http://www.mynewsdesk.com/fi/pressroom/astrazeneca/document/view/valmisteyhteenveto-vimovo-kipulaeaekkeelle-16179?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document http://www.mynewsdesk.com/fi/pressroom/astrazeneca/document/view/valmisteyhteenveto-vimovo-kipulaeaekkeelle-16179?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document AstraZeneca AB